Neuphoria Therapeutics (NEUP) EBT (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported EBT for 4 consecutive years, with -$539856.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, EBT fell 104.83% year-over-year to -$539856.0 in Q1 2026; TTM through Mar 2026 was -$24.1 million, a 530.6% decrease from a year earlier, with the FY2025 full-year figure at -$7.1 million, up 54.35% from the prior year.
• EBT was -$539856.0 for Q1 2026 at Neuphoria Therapeutics, down from $1.8 million in the prior quarter.
• Over five years, EBT peaked at $11.2 million in Q1 2025 and troughed at -$15.4 million in Q2 2025.
• A 4-year average of -$2.8 million and a median of -$2.7 million in 2024 frame the typical range for EBT.
• The widest YoY moves for EBT: up 504.85% in 2025, down 961.0% in 2025.
• Over 4 years, EBT stood at -$4.6 million in 2023, then jumped by 57.91% to -$1.9 million in 2024, then soared by 194.7% to $1.8 million in 2025, then plunged by 129.51% to -$539856.0 in 2026.
• The last three EBT figures came in at -$539856.0 (Q1 2026), $1.8 million (Q4 2025), and -$9.9 million (Q3 2025), per Business Quant data.